<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471559</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-DDS</org_study_id>
    <nct_id>NCT03471559</nct_id>
  </id_info>
  <brief_title>Cannabidiol - an in Vivo Innovative Drug Delivery Study</brief_title>
  <official_title>Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basic characterization of the drug delivery system for cannabidiol. A comparative
      bioavailability study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to investigate an innovative pharmaceutical preparation of cannabidiol. Thus,
      a comparative bioavailability study will be conducted, comparing cannabidiol capsules
      (reference formulation) with an intranasal cannabidiol gel (test formulation), with the
      further aim to find an appropriate dosing of the new pharmaceutical preparation. The
      intranasal administration may also be suitable to reduce the high variability in the
      bioavailability of cannabidiol observed for the current oral administration.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 4, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of single dose - area under the curve (AUC(0-t)), AUC(0-∞))</measure>
    <time_frame>36 hours</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of single dose - residual area</measure>
    <time_frame>36 hours</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of single dose - maximum concentration (Cmax)</measure>
    <time_frame>36 hours</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of single dose - time to reach Cmax (tmax)</measure>
    <time_frame>36 hours</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of single dose - elimination half life (t1/2)</measure>
    <time_frame>36 hours</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of single dose - elimination rate constant (λz)</measure>
    <time_frame>36 hours</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of multiple dosing - area under the curve (AUC(τ))</measure>
    <time_frame>9 days</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of multiple dosing - maximum concentration (Cmax,ss)</measure>
    <time_frame>9 days</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of multiple dosing - time to reach Cmax (tmax,ss)</measure>
    <time_frame>9 days</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of multiple dosing - elimination half life (t1/2,ss (τ=12h))</measure>
    <time_frame>9 days</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of multiple dosing - steady state accumulation ratio</measure>
    <time_frame>9 days</time_frame>
    <description>reference formulation compared to new formulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regular laboratory testing</measure>
    <time_frame>36h or 9 days</time_frame>
    <description>standard laboratory blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography - QTc time</measure>
    <time_frame>36 hours or 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs - body temperature</measure>
    <time_frame>36 hours or 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs - blood pressure</measure>
    <time_frame>36 hours or 9 days</time_frame>
    <description>Systolic and diastolic blood pressure reported in millimetres of mercury (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs - pulse rate</measure>
    <time_frame>36 hours or 9 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pharmacokinetics, Bioavailability</condition>
  <arm_group>
    <arm_group_label>Reference formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cannabidiol capsule, 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>single or multiple dosing</description>
    <arm_group_label>Reference formulation</arm_group_label>
    <arm_group_label>New formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent given by the subject

          -  Negative drug screening at the time of screening

          -  Non-smoking

          -  In female participants in fertile age, reliable contraception, which means
             contraception's Pearl index is equal to or smaller than 1.

          -  Body Mass Index between 18.5 kg/m2 and 30 kg/m2

        Exclusion Criteria:

          -  Lack of accountability

          -  Pregnancy or lactation phase in females at the time of screening

          -  Any known psychiatric or neurological illness in the participant's history.

          -  Known family history regarding psychiatric disorders with an increased lifetime risk
             for psychiatric disorders in the participant (investigators qualified judgement)

          -  Relevant use of cannabis (which is defined on the present state of knowledge as more
             than five times lifetime consumption and/or more than two consumptions during the last
             year)

          -  Consumption of any illicit drugs (except cannabis in history, see above)

          -  Severe physical (internal) or neurological illness, especially cardiovascular, renal,
             advanced respiratory, haematologic or endocrinologic disorders or infectious diseases
             (acute hepatitis A, B or C or HIV) assessed at the time of the screening by the
             subject's history, clinical examination and laboratory testing, as assessed by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Fuhr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department I of Pharmacology, University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F. Markus Leweke, MD</last_name>
    <phone>+49 621 1703 2302</phone>
    <email>leweke@cimh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department I of Pharmacology, University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uwe Fuhr, MD</last_name>
      <email>uwe.fuhr@uk-koeln.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

